Skip to main content
. 2023 Mar 6;17:17534666231158279. doi: 10.1177/17534666231158279

Figure 3.

Figure 3.

A summary of the patient’s clinical course.

The decline in forced vital capacity accelerated with the appearance of joint involvement.

anti-CCP antibody, anti-cyclic citrullinated peptide antibody; BAL, bronchoalveolar lavage; PSL, prednisolone; SASP, salazosulfapyridine; TBLB, transbronchial lung biopsy.